John Matthew Maris

faculty photo
Professor of Pediatrics
Member, Hematology/Oncology Fellowship Committee, Children's Hospital of Philadelphia, University of Pennsylvania
Co-Chair, Genetics, Genomics and Pediatric Diseases Research Affinity Group, Children's Hospital of Philadelphia
Member, Abramson Family Cancer Research Institute, University of Pennsylvania
Giulio D'Angio Endowed Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Oncology
Colket Translational Research Building
3501 Civic Center Boulevard #3060

4399
Philadelphia, PA 19104-4318
Office: 215 590 5244
Fax: 267 426 0685
Education:
B.S. (Biology)
Wheeling College , 1983.
M.D. (Medicine)
University of Pennsylvania, 1989.
Permanent link
 

Description of Itmat Expertise

Dr. Maris's research focuses on translational genomics and genetics of neuroblastoma.

Selected Publications

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM: Defining Risk Factors for Chemotherapeutic Intervention in Infants with Stage 4S Neuroblastoma: A Report From Children's Oncology Study ANBL0531. J Clin Oncol. Nov 2018.

Dubois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith KC, Granger M, Weiss B, Park JR, Macy ME, Cohn SL, Yanik GA, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.: Phase 2 Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res August 2018.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MD, Tenney SC, Smith M, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL: Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol July 2018.

Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, Maris JM, Schleiermacher G, Boeva V: QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics June 2018.

Ozkayaynak MF, Gilamn AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol June 2018.

Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ1, Iyer A1, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A: Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discov May 2018.

Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagraraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, Sondel PM, Seeger RC, Maris JM, Khan J: Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma. Clin Cancer Res. May 2018.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J: Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature Mar 2018.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K: Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst. Mar 2018.

Matsuno Ryosuke, Gifford Andrew J, Fang Junming, Warren Mikako, Lukeis Robyn E, Trahair Toby, Sugimoto Tohru, Marachelian Araz, Asgharzadeh Shahab, Maris John M, Ikegaki Naohiko, Shimada Hiroyuki: Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society Page: 1093526617749670, Jan 2018.

back to top
Last updated: 12/04/2018
The Trustees of the University of Pennsylvania